StrokeDx is a human health startup developing next-generation technology that will transform how strokes are diagnosed and treated. Based on technology developed at Caltech, the innovative, portable StrokeDx neuroimaging device will dramatically reduce the time to diagnose and treat strokes. Their solution leverages machine learning and AI to fuel diagnostic accuracy and imaging capabilities. The global stroke diagnostics market is expected to be ~$5.5B by 2028. Most recently, StrokeDx has been named to the MedTech Innovator (MTI) 2023 Cohort. MTI is the world’s largest and most competitive medical device accelerator. Learn more about the company at https://www.stroke-dx.com/
The discussion kicked off with a presentation and introductory remarks from StrokeDx Co-founders Shane Shahrestani and Alexander Ballatori, followed by Q&A with Freeflow, and concluded with questions from the audience.
List of speakers:
Shane Shahrestani, Co-Founder at StrokeDx
Alexander Ballatori, Co-Founder at StrokeDx
David Fleck, Founder and Managing Partner, Freeflow Ventures
Kevin Barrett, Managing Partner, Freeflow Ventures
Other articles
December 19, 2025
Iambic Therapeutics: Inside the Company Advancing and Accelerating AI in Drug Development
How does a techbio company get to clinic faster and scale a platform business?…
December 16, 2025
From Science to Startup – Freeflow Scientific Advisory Board Insights from Caltech & Berkeley
From Science to Startup: Insights from Caltech and Berkeley featuring: Barbara…
March 14, 2025
Flion Energy: Powering the New Geothermal
Flion Energy is a Freeflow Fund One portfolio company developing novel…



